Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Leukemia
|
December 15, 2019
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
Marco Frigeni, Caroline Besson, Carlo Visco, et al.
Hemasphere
|
February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
Hemasphere
|
June 7, 2023
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study
Irene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, et al.
Cancers
|
December 30, 2025
Secondary Genetic Events and Their Relationship to <i>TP53</i> Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)
Maria Elena Carazzolo, Francesca Maria Quaglia, Antonino Aparo, et al.
The Oncologist
|
December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas
Michele Merli, Marco Frigeni, Laurent Alric, et al.
Haematologica
|
April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Hematological Oncology
|
July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
Francesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Haematologica
|
March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Leukemia
|
December 15, 2019
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
Marco Frigeni, Caroline Besson, Carlo Visco, et al.
Hemasphere
|
February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
Hemasphere
|
June 7, 2023
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study
Irene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, et al.
Cancers
|
December 30, 2025
Secondary Genetic Events and Their Relationship to <i>TP53</i> Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)
Maria Elena Carazzolo, Francesca Maria Quaglia, Antonino Aparo, et al.
The Oncologist
|
December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas
Michele Merli, Marco Frigeni, Laurent Alric, et al.
Haematologica
|
April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Hematological Oncology
|
July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
Francesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Haematologica
|
March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Emilio Iannitto, Simone Ferrero, Côme Bommier, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Page
of 12